Parkinson's disease, proteins, and prions: Milestones

Movement Disorders

Volumn 26, Issue 6, 2011, Pages 1056-1071

  Olanow, C Warren ^a   Mcnaught, K ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Tourette Syndrome Association   (United States)

Author keywords

PD; Prions; Proteins

Indexed keywords

ALPHA SYNUCLEIN; ANSAMYCIN DERIVATIVE; BENZOQUINONE; DEXAMETHASONE; GELDANAMYCIN; GLUCOCORTICOID; LEUCINE RICH REPEAT KINASE 2; OLIGOMER; PARKIN; PROTEASOME; PROTEIN; RADICICOL; UBIQUITIN;

AGGRESOME; AUTOPHAGY; DOPAMINERGIC NERVE CELL; ETIOLOGY; GENE MUTATION; HUMAN; LEWY BODY; LYSOSOME; PARKINSON DISEASE; PRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW;

ANIMALS; AUTOPHAGY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEWY BODIES; MUTATION; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PRION DISEASES; PRIONS; UBIQUITIN;

EID: 79957620836     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23767     Document Type: Review

References (188)

1. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996; 55: 259-272.
2. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24: 197-211.
3. Lewy FH. Paralysis agitans. I pathologische anatomie. Berlin, Germany: Springer; 1912.
4. Tretiakoff C. Contribution a l'etude de l'anatomie pathologique du locus niger de Soemmering avec quelques deductions relatives a la pathogenie des troubles du tonus musculaires et de la maladie de Parkinson. University of Paris; 1919.
5. Lennox G, Lowe J, Morrell K, Landon M, Mayer RJ. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry. 1989; 52: 67-71.
6. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998; 95: 6469-6473.
7. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol. 2008; 64: 485-491.
8. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol. 1993; 60: 609-612.
9. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol. 2006; 59: 591-596.
10. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003; 426: 895-899.
11. Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 2007; 6: 352-361.
12. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev. Mol Cell Biol. 2005; 6: 79-87.
13. de Duve C. The lysosome turns fifty. Nat Cell Biol. 2005; 7: 847-849.
14. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008; 132: 27-42.
15. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998; 67: 425-479.
16. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001; 70: 503-533.
17. Demartino GN, Gillette TG. Proteasomes: machines for all reasons. Cell. 2007; 129; 659-662.
18. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000; 10: 524-530.
19. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci. 2002; 16: 2136-2148.
20. Olanow CW, Perl DP, DeMartino GN, McNaught KS. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 2004; 3: 496-503.
21. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000; 290: 985-989.
22. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem. 2004; 279: 4625-4631.
23. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276: 2045-2047.
24. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998; 18: 106-108.
25. Zarranz JJ, Allegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004; 55: 164-173.
26. Muenter MD, Forno LS, Hornykiewicz O, et al. Hereditary form of parkinsonism-dementia. Ann Neurol. 1998; 43: 768-781.
27. Kotzbauer PT, Giasson BI, Kravitz AZ, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol. 2004; 187: 279-288.
28. Duda JE, Giasson BI, Mabon ME, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (Berl). 2002; 104: 7-11.
29. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004; 364: 1167-1169.
30. Ibáñez P, Bonnet AM, Débarges B, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004; 364: 1169-1171.
31. Singleton AB. et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302: 841.
32. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988; 8: 2804-2815.
33. Solano SM, Miller DW, Augood SJ, Young AB, Penney JB Jr. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann Neurol. 2000; 47: 201-210.
34. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001; 2: 492-501.
35. Abeliovich A, Schmitz Y, Fariñas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000; 25: 239-252.
36. Ferreon AC, Gambin Y, Lemke EA, Deniz AA. Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc Natl Acad Sci U S A. 2009; 106: 5645-5650.
37. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996; 35: 13709-13715.
38. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998; 4: 1318-1320.
39. Conway KA, Lee SJ, Rochel JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000; 97: 571-576.
40. Lashuel HA, Petre BM, Wall J, et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol. 2002; 322: 1089-1102.
41. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003; 26: 267-298.
42. Pandey N, Schmidt RE, Galvin JE. The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp Neurol. 2006; 197: 515-520.
43. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM, et al. Degradation of alpha-synuclein by proteasome. J Biol Chem. 1999; 274: 33855-33858.
44. Liu CW, Corboy MJ, DeMartino GN, Thomas PJ. Endoproteolytic activity of the proteasome. Science. 2003; 299: 408-411.
45. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci. 2004; 24: 1888-1896.
46. Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet. 2001; 10: 919-926.
47. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J Biol Chem. 2003; 278: 11753-11759.
48. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305: 1292-1295.
49. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest. 2008; 118: 777-788.
50. Winslow A, Rubinsztein DC. The Parkinson disease protein α-synuclein inhibits autophagy. Autophagy. 2011 [Epub ahead of print].
51. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001; 292: 1552-1555.
52. Zhang NY, Tang Z, Liu CW. Alpha-synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J Biol Chem. 2008; 283: 20288-20298.
53. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson's disease. J Biol Chem. 2005; 280: 22670-22678.
54. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000; 404: 394-398.
55. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A. 2003; 100: 2884-2889.
56. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000; 287: 1265-1269.
57. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci. 2008; 28: 247-256.
58. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009; 35: 385-398.
59. Matsumine H, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet. 1997; 60: 588-596.
60. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998; 392: 605-608.
61. Lüucking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med. 2000; 342: 1560-1567.
62. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology. 1998; 51: 890-892.
63. Horowitz JM, Vernace VA, Myers J, et al. Immunodetection of Parkin protein in vertebrate and invertebrate brains: a comparative study using specific antibodies. J Chem Neuroanat. 2001; 21: 75-93.
64. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000; 25: 302-305.
65. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem. 2000; 275: 35661-35664.
66. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell. 2001; 105: 891-902.
67. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A. 2000; 97: 13354-13359.
68. Lim KL, Chew KC, Tan JM, et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci. 2005; 25: 2002-2009.
69. Sakata E, Yamaguchi Y, Kurimoto E, et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. 2003; 4: 301-306.
70. Imai Y, Soda M, Hatakeyama S, et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell. 2002; 10: 55-67.
71. Cyr DM, Hohfeld J, Patterson C. Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem Sci. 2002; 27: 368-375.
72. Dächsel JC, Lücking CB, Deeg S, et al. Parkin interacts with the proteasome subunit alpha4. FEBS Lett. 2005; 579: 3913-3919.
73. Shimura H, Hattori N, Kubo S, et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol. 1999; 45: 668-672.
74. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of {alpha}-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 2001; 293: 263-269.
75. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron. 2003; 37: 911-924.
76. Itier JM, Ibanez P, Mena MA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet. 2003; 12: 2277-2291.
77. Goldberg MS, Fleming SM, Palacino JJ, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem. 2003; 278: 43628-43635.
78. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A. 2005; 102: 2174-2179.
79. Lincoln SJ, Maraganore DM, Lesnick TG, et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov Disord. 2003; 18: 1306-1311.
80. Leroy E, Bower R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998; 395: 451-452.
81. Auberger et al. Is the PARK5 I93M mutation a cause of Parkinson's disease with cognitive deficits and cortical Lewy pathology? 16th International Congress on Parkinson's Disease and Related Disorders Berlin, PT042; 2005.
82. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science. 1989; 246: 670-673.
83. Nishikawa K, Li H, Kawamura R, et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun. 2003; 304: 176-183.
84. Osaka H, Wang YL, Takada K, et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet. 2003; 12: 1945-1958.
85. McNaught KS, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem. 2002; 81: 301-306.
86. Wintermeyer P, Krüger R, Kuhn W, et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport. 2000; 11: 2079-2082.
87. Maraganore DM, Lesnick TG, Elbaz A, et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol. 2004; 55: 512-521.
88. Healy DG, Abou-Steinman PM, Casas JP, et al. UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol. 2006; 59: 627-633.
89. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol. 2002; 51: 296-301.
90. Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004; 44: 595-600.
91. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004; 44: 601-607.
92. Nichols WC, Pankratz N, Hernandez D, et al; Parkinson Study Group-PROGENI investigators. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet. 2005; 365: 410-412.
93. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet. 2005; 365: 415-416.
94. Healy DG, Falchi M, O'sullivan SS, et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008; 7: 583-590.
95. Wider C, Dickson DW, Wszolek ZK. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis. 2010; 7: 175-179.
96. Vitte J, Traver S, Maués De Paula A, et al. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol. 2010; 69: 959-972.
97. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci. 2010; 11: 791-797.
98. Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med. 2010; 16: 998-1000.
99. Li X, Tan Y, Poulose S, Olanow CW, Huang X-Y, Yue Z. Leucine-rich repeat kinase 2/PARK8 possesses GTPase activity that is altered in familial Parkinson' disease R1441C/G mutant. J Neurochem. 2007; 103: 238-247.
100. Melrose HL, Dächsel JC, Behrouz B, et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis. 2010; 40: 503-517.
101. Lin X, Parisiadou L, Gu XL, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron. 2010; 64: 807-827.
102. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci. 2001; 2: 589-594.
103. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003; 302: 819-822.
104. Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson's disease. Mov Disord. 2006; 21: 1806-1823.
105. Gupta A, Dawson VL, Dawson TM. What causes cell death in Parkinson's disease? Ann Neurol. 2008; 64(Suppl 2): S3-S15.
106. Ventruti A, Cuervo AM. Autophagy and neurodegeneration. Curr Neurol Neurosci Rep. 2007; 7: 443-451.
107. El-Khodor BF, Kholodilov NG, Yarygina O, Burke RE. The expression of mRNAs for the proteasome complex is developmentally regulated in the rat mesencephalon. Brain Res Dev Brain Res. 2001; 129: 47-56.
108. Gaczynska M, Osmulski PA, Ward WF. Caretaker or undertaker? The role of the proteasome in aging. Mech Ageing Dev. 2001; 122: 235-254.
109. Zeng BY, Medhurst AD, Jackson M, Rose S, Jenner P. Proteasomal activity in brain differs between species and brain regions and changes with age. Mech Ageing Dev. 2005; 126: 760-766.
110. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem. 1998; 70: 268-275.
111. Chu Y, Kordower JH. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis. 2007; 25: 134-149.
112. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988; 51: 745-752.
113. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol. 2003; 179: 38-45.
114. Tofaris GK, Razzaq A, Ghetti B, Lilley K, Spillantini MG Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. 2003; 278: 44405-44411.
115. Furukawa Y, Vigouroux S, Wong H, et al. Brain proteasomal function in sporadic Parkinson's disease and related disorders. Ann Neurol. 2002; 51: 779-782.
116. Grünblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle. J Neural Transm. 2004; 111: 1543-1573.
117. McNaught KS, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem. 2002; 81: 301-306.
118. Petrucelli L, O'Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 2002; 36: 1007-1019.
119. Rideout HJ, Lang-Rollin IC, Savalle M, Stefanis L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem. 2005; 93: 1304-1313.
120. McNaught KSP, Bjorklund LM, Belizaire R, Jenner P, Olanow CW. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport. 2002; 13: 1437-1441.
121. Fornai F, Lenzi P, Gesi M, et al. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci. 2003; 23: 8955-8966.
122. Miwa H, Kubo T, Suzuki A, Nishi K, Kondo T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci Lett. 2005; 380: 93-98.
123. McNaught KS, Perl DP, Brownell A-L, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol. 2004; 56: 149-162
124. Schapira AH, Cleeter MW, Muddle JR, Workman JM, Cooper JM, King RH. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol. 2006; 60: 253-255.
125. Bukhatwa S, Zeng BY, Rose S, Jenner P. The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain. Brain Res. 2010; 1354: 236-242.
126. Nair VD, McNaught KS, González-Maeso J, Sealfon SC, Olanow CW. p53 Mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem. 2006; 281: 39550-560.
127. Kordower JH, Kanaan NM, Chu Y, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol. 2006; 60: 264-268.
128. Bové J, Zhou C, Jackson-Lewis V, et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006; 60: 260-264.
129. Bedford L, Hay D, Devoy A, et al. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci. 2008; 28: 8189-8198.
130. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol. 1997; 12: 25-31.
131. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol. 2010; 67: 1464-1472.
132. Dehay B, Bove J, Rodriguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci. 2010; 30: 12535-12544.
133. Chen Y, Millan-Ward E, Kong J, Israels SJ, Gibson SB. Mitochondrial electrontransport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. J Cell Sci. 2007; 120: 4155-4166.
134. Dagda RK, Zhu J, Kulich SM, Chu CT. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy. 2008; 4: 770-782.
135. Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, Chu CT. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol. 2007; 170: 75-86.
136. Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006; 441: 880-884.
137. Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006; 441: 885-889.
138. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009; 361: 1651-1661.
139. Saunders-Pullman R, Hagenah J, Dhawan V, et al. Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord. 2010; 250: 1364-1372.
140. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008; 14: 504-506.
141. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. 2008; 14: 501-503.
142. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008; 23: 2303-2306.
143. Olanow CW. Goetz CG, Kordower JH, et al. A double blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003; 54: 403-414.
144. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathologic evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Eng J Med. 1995; 332: 1118-1124.
145. Lee H-J, Patel S, Lee S-J Intravesicular localization and exocytosis of α-synuclein and its aggregates. J Neurosci. 2005; 25: 6016-6024.
146. Lee H-J, Suk JE, Bae EJ, Lee JH, Paik SR, Lee S-J Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol. 2008; 40: 1835-1849.
147. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2010; 106: 13010-13015.
148. Hansen C, Angot E, Bergström AL, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 2011; 121: 715-725.
149. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A. 2010; 106: 12571-12572.
150. Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998; 95: 13363-13383.
151. Prusiner SB. Prions. In: Knipe DM, Howley PM, Griffin DE, et al, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2007: 3059-3092.
152. Jao CC, Hegde BG, Chen J, Haworth IS, Langen R. Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc Natl Acad Sci U S A. 2009; 105: 19666-19671.
153. Telling GC, Scott M, Mastrianni J, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell. 1995; 83: 79-90.
154. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One. 2010; 5: e8762.
155. Schapira AHV, Olanow CW. Neuroprotection in Parkinson's disease: myths, mysteries, and misconceptions. JAMA. 2004; 291: 358-364.
156. Ding Q, Keller JN. Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins. J Neurochem. 2001; 77: 1010-1017.
157. Shashidharan P, Paris N, Sandu D, et al. Overexpression of TorsinA in PC12 cells protects against toxicity. J Neurochem. 2004; 88: 1019-1025.
158. Zourlidou A, Payne Smith MD, Latchman DS. HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. J Neurochem. 2004; 88: 1439-1448.
159. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem. 2004; 279: 25497-25502.
160. Lindersson E, Beedholm R, Hojrup P, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem. 2004; 279: 12924-12934.
161. Auluck PK, Chan E, Trojanowski JQ, Lee V, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model of Parkinson's disease. Science. 2002; 295: 865-868.
162. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem. 1999; 42: 260-266.
163. Hargitai J, Lewis H, Boros I, et al. Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun. 2003; 307: 689-695.
164. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004; 10: 402-405.
165. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 1998; 94: 471-480.
166. Sittler A, Lurz R, Lueder G, et al. Geldanamycin activates a heat shock response inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet. 2001; 10: 1307-1315.
167. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A. 1994; 91: 8324-8328.
168. Tanaka M, Machida Y, Niu S, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med. 2004; 10: 148-154.
169. Singer MA, Lindquist S. Multiple effects of trehalose on protein folding in vitro and in vivo. Mol Cell. 1998; 1: 639-648.
170. McLean PJ, Klucken J, Shin Y, Hyman BT. Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun. 2004; 321: 665-669.
171. Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila. Nat Med. 2002; 8: 1185-1186.
172. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science. 2003; 302: 1769-1772.
173. Lewis KA, Yaeger A, DeMartino GN, Thomas PJ. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations. J Bioenerg Biomembr. 2010; 42: 85-95.
174. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron. 2005; 46: 857-868.
175. Yu WH, Dorado B, Figueroa HY, et al. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol. 2009; 175: 736-747.
176. Marinovic AC, Zheng B, Mitch WE, Price SR. Ubiquitin (UbC) expression in muscle cells is increased by glucocorticoids through a mechanism involving Sp1 and MEK1. J Biol Chem. 2002; 277: 16673-16681.
177. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol. 1993; 264: 668-676.
178. Dardevet D, Sornet C, Taillandier D, Savary I, Attaix D, Grizard J. Sensitivity and protein turnover response to glucocorticoids are different in skeletal muscle from adult and old rats. Lack of regulation of the ubiquitin-proteasome proteolytic pathway in aging. J Clin Invest. 1995; 96: 2113-2119.
179. Chrysis D, Underwood LE. Regulation of components of the ubiquitin system by insulin-like growth factor I and growth hormone in skeletal muscle of rats made catabolic with dexamethasone. Endocrinology. 1999; 140: 5635-5641.
180. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294: 1704-1708.
181. Du J, Mitch WE, Wang X, Price SR. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B. J Biol Chem. 2000; 275: 19661-19666.
182. Combaret L, Taillandier D, Dardevet D, et al. Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles. Biochem J. 2004; 378: 239-246.
183. Chandra S, Fornai F, Kwon HB, et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A. 2004; 101: 14966-14971.
184. Büeler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993; 73: 1339-1347.
185. Büeler H, Fisher M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 1992; 356: 577-582.
186. Prusiner SB, Groth D, Serban A, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A. 1993; 90: 10608-10612.
187. Tremblay P, Meiner Z, Galou M, et al. Doxycyline control of prion protein transgene expression modulates prion disease in mice. Proc Natl Acad Sci U S A. 1992; 95: 12580-12585.
188. Safar JG, DeArmond SJ, Kociuba K, et al. Prion clearance in bigenic mice. J Gen Virol. 2005; 86: 2913-2923.